Dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction – a practical approach
Because of its frequent occurrence, poor prognosis, low quality of life of patients accompanying the disease and high costs associated with treatment heart failure is a significant health problem in modern cardiology. The treatment of patients with heart failure and reduced ejection fraction (HFrEF)...
Guardado en:
Autor principal: | Jadwiga Nessler |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Termedia Publishing House
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7df11093d00449928650f3e7ff95d42c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin
por: Avgerinos I, et al.
Publicado: (2019) -
Intensification of glucose-lowering treatment in patients with diabetes mellitus type 2 on insulin therapy: Perspectives of dapagliflozin
por: Olga Yuryevna Sukhareva, et al.
Publicado: (2016) -
Patient considerations in type 2 diabetes – role of combination dapagliflozin–metformin XR
por: Kuecker CM, et al.
Publicado: (2016) -
Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction
por: Steffen Pabel, et al.
Publicado: (2021) -
Left ventricular systolic dysfunction among nocturnal myocardial infarctions
por: A Ghaemian, et al.
Publicado: (2004)